Correction regarding press release: Québec to acquire advanced linear accelerators to meet growing need for advanced cancer care
QUÉBEC, Canada, February 17, 2020 – Elekta (EKTA-B.ST) announced February 11 that the Québec government’s procurement representative, Groupe d’Approvisionnement Commun de l’Est du Québec (GACEQ), has published a notice of intent to award a sole source contract to Elekta for an order of 18 advanced linear accelerators (linacs) over the next five years. Elekta was selected after a pan-Canadian public tendering process in which Québec was a participant.
Pending conclusion, the sole source contract has a total order value of approximately CAD 56 million (SEK 407 million) for Elekta.
It is widely recognized that more than half of all cancer patients require radiation therapy*. And according to the Quebec Cancer Foundation, 55,600 new cancer cases are diagnosed in the province each year and the number is expected to continue increasing. However, with this order, the province of Quebec is actively meeting the treatment needs of its inhabitants.
Richard Hausmann, Elekta’s President and CEO, says: “These radiation therapy devices will have a significant impact on the lives of cancer patients and their families in Québec. It is satisfying to see that the Health Ministry and GACEQ have chosen solutions, which provide high levels of accuracy, precision and efficiency. Elekta’s Versa HD allows hospitals to offer treatment modalities such as stereotactic body radiation therapy and stereotactic radiosurgery, enabling hypofractionation which increases the quality of life for patients.”
*Radiation therapy and cancer control in developing countries: Can we save more lives?
doi: 10.7150/ijms.17288
# # #
For further information, please contact:
Mattias Thorsson, Head of Corporate Communications and Public Affairs
Tel: +46 70 865 8012, e-mail: [email protected]
Time zone: CET: Central European Time
Cecilia Ketels, Head of Investor Relations
Tel: +46 76 611 76 25, e-mail: [email protected]
Time zone: CET: Central European Time
This is information that Elekta AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was resubmitted for publication at 17:00 CET on February 17, 2020. (REGMAR)
About Elekta
For almost five decades, Elekta has been a leader in precision radiation medicine. Our nearly 4,000 employees worldwide are committed to ensuring everyone in the world with cancer has access to – and benefits from – more precise, personalized radiotherapy treatments. Headquartered in Stockholm, Sweden, Elekta is listed on NASDAQ Stockholm Exchange. Visit elekta.com or follow @Elekta on Twitter.